Development of parotitis after radioiodine therapy in a differentiated thyroid cancer patient: Case report

Diferansiyeye tiroid kanser hastasında radyoiyot tedavisi sonrası parotit gelişimi: Olgu sunumu

*Zekiye Hasbek, **Kasım Durmuş, ***Aynur Engin, **Emine Elif Altuntaş

*Cumhuriyet University, School of Medicine, Department of Nuclear Medicine, Sivas
** Cumhuriyet University, School of Medicine, Department of Otolaryngology, Sivas
*** Cumhuriyet University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Sivas

Corresponding author: Dr. Zekiye Hasbek, Department of Nuclear Medicine, Cumhuriyet University, TR-58140 Sivas.
E-mail: hasbekz@yahoo.com

Received/Accepted: September 08, 2015 / January 04, 2016

Conflict of interest: There is not a conflict of interest.

SUMMARY

In this article, we report a 51 years old female patient treated with radioactive iodine (RAI-\(^{131}\)I) treatment for thyroid papillary carcinoma and developing parotitis on the 24 hour following treatment. Sialoadenitis after high dose ablative therapy with \(^{131}\)I is a relatively common complication with a low clinical impression. Taste alteration or loss, and nausea and vomiting due to radiation sickness are the other most frequent side effects. Xerostomia is an important problem increasing morbidity of the patients. For this reason, it is important to prevent xerostomia by following serum amylase levels in symptomatic patients. By taking into account that not only bacterial and viral factors but also radiation may cause sialadenitis, one has to rule out other parotitis possibilities by clinical and laboratory findings before claiming that salivary gland enlargement developing after radioiodine is a complication of radiation. Moreover, history of RAI treatment should be given importance in patients applying either to emergency services or to Ear Nose Throat and Infectious Diseases Department with dry mouth.

Keywords: Radioiodine therapy, differentiated thyroid carcinoma, parotitis

ÖZET


Anahtar sözcükler: Radyoiyot tedavi, diferansiyeye tiroid kanserim, parotit
INTRODUCTION
Radioiodine (¹³¹I) concentrates in thyroid cells and it can destroy thyroid cells. So, in differentiated thyroid cancer patients, radioiodine therapy can be used to destroy any thyroid tissue not removed by surgery or to treat spread to lymph nodes and other parts of the body [1]. For an effective RAI therapy, thyroid-stimulating hormone (TSH) levels of the patients should be high. TSH stimulates thyroid tissue (and cancer cells) to take up radioactive iodine. Serious acute complications are extremely rare during RAI therapy. However, some early complications can be seen. Short-term side effects of RAI treatment may include neck tenderness and swelling, nausea and vomiting due to radiation sickness, swelling and tenderness of the salivary glands, dry mouth, and taste alteration.

Following RAI administration, ensuring hydration, drinking lemon juice, suck-ing lemon candies, treating constipation with laxatives, and using antiemetics help both remission of symptoms and decrease the exposure of bladder, salivary glands and colon to radioactivity. We present a case where the patient developed radiation sialadenitis after radiative iodide therapy for thyroid papillary cancer that resulted in a high level of serum amylase and severe parotid swelling.

CASE REPORT
A 51 years old female patient undergoing total thyroidectomy for thyroid papillary carcinoma was referred to the Nuclear Medicine Department of Cumhuriyet University for radioactive iodine (RAI) treatment with 131I. In her neck ultrasonography before ablation therapy with RAI, a few lymph nodes were observed in both cervical chains. Moreover, a thrombosed appearance originating from the left ex-ternal carotid artery of the left thyroid gland with a blind ending at the thyroid gland, and a thrombosed appearance of the superior thyroid artery with min-imal arterial flow at the lumen area were observed. There was no hypper-mia, edema or heat increase in the parotid region before starting the treat-ment.

Her thorax X-ray was normal. Thyroid scintigraphy performed with Tc99m pertechnetate before ablation revealed a minimal residual thyroid tissue uptake at the left lobe of the thyroid gland. During her hospitalization, thyroid function tests revealed: fT3:1.52 pg/mL, fT4: 0.23 ng/dL, TSH: 96.93 µU/mL, Anti-thyroglobulin antibody (Anti-Tg Ab): 0.001 IU/mL, thyroglobulin (Tg): 0.51 ng/mL. Following oral administration of 100 mCi 1-131 capsule, the patient was isolated in an iodine room. The patient was recom-mended to drink plenty of water, suck candy and eat lemon. Twenty four hours after the RAI therapy, the patient was found to have a bilateral parotid hardening and swelling. The patient had no additional symptoms such as pain, fever, etc. Her history was re-examined.

It was learned that the patient had a complaint of dry mouth after total thyroidectomy. The patient had no history of tumor or medications affect-ing salivary glands such as antihista-mines, anticholinergics or antispasmodics. Thus, a consultation was re-quested from the Ear Nose Throat and Infectious Diseases (ENT) Department. ENT consultation revealed bilateral parotid gland swelling prominent on the right side while anterior rhinoscopy showed a normal bilateral space. The oral mucosa appeared normally moist and not inflamed. Autoscopic examina-tion showed that the bilateral external auditory canal was natural and bilateral tympanic membrane was intact. The systematic examination of the patient was normal and there was no fever. Infectious dis-eases consultation showed a parotid swelling and enduration with-out any infectious cause. Examinations revealed leukocytosis with a leukocyte value of 12.14 where neutrophils ac-counted for 90%, lymphocytes for 7% and monocytes for 1.7%.

Her blood amylase level was found to be above the normal level, namely 1595 U/L. An infectious dis-eases consultation revealed that mumps-specific IgG antibody was posi-tive and IgM antibody was negative. No additional recommendations were made to increase the fluid support of the patient. Approxi-mately 30 hours after 131I administration, the parotid swelling of the patient disappeared. On the post-operative 8th day, 131I whole-body scintigraphy (WBS) was per-formed using large field-of-view, dual-head gamma camera (GCA7100-Toshiba) equipped with high energy parallel-hole collimator. WBS (whole-body scintigraphy) revealed increased iodine uptake at the right parotid area and an uptake focus compatible with the residual thyroid tissue at
the neck region (Figure 1). Hemogram and serum amylase levels were measured again. After seven days, serum amylase was in normal values (95U/L). Also hemogram levels were normal. The patient was evaluated as having parotitis due to radiiodine.

**DISCUSSION**

Radioiodine is concentrated and secreted into the saliva. Thus, salivary gland dysfunction is the most frequent complication of ablation therapy with radioiodine. Due to deep hypo-thyroidism, glomerular infiltration is decreased at the time of ablation therapy. For this reason, radioiodine is cleared from circulation much later and causes stasis of radiiodine in the salivary glands. In the literature, the ratio of sialadenitis has been reported to be between 2.8% to 33% after RAI therapy [2]. Dose related damage to the salivary paren-chyma results from the 131I irradiation [Jeong]. Transient sialadenitis is rare with smaller doses of radio-active iodined [3].

Salivary gland dysfunction is more common after repeated 131I ad-ministration [4]. Swelling and pain of salivary gland are the most common symptoms in early sialadenitis while xerostomia is the most prominent symptom in chronic sialadenitis after RAI therapy. An YS et al. [5] found the ratio of late-phase (mean 338 days) symptomatic sialadenitis as 10% after RAI therapy. Early sialadenitis occurs in a short time after RAI therapy with swelling and pain symptoms and usual-ly subsides over a few days spontaneously. Sialagogues, warm compress, steroids and cholinergic medications may be necessary. In recent studies, use of sia-lendoscopy has been reported in severe and refractory cases [6].

When compared to mucous cells, serous cells have a greater ability to trap iodide. Parotid gland involve-ment is observed more frequently as it contains more serous cells than mucous cells [7]. Moreover, high mucin secre-tion in the submandibular glands pro-duce these glands from exposure to radi-ation [5]. Interestingly, although its rea-son has not been fully explained yet, there are studies reporting that the right parotid gland is affected more [5]. Moreover, Jeong et al. [8] found that xerostomia is most frequently associat-ed with submandibular gland dysfunction. Mandel et al reported that, in co-njunction with the radiation sialadeni-tis, secondary complications may include xerostomia, taste alterations, infection, increases in caries, facial nerve in-volve-ment, stomatitis, candidiasis, and neoplasia [9]. Ade-quate hidration, sucking sweets or lemon juice advo-cates to reduce radiation damage to the salivary glands.

In a study conducted by Solans et al. [10] on 79 patients, 32.9% of the patients had subjective xerostomia and 25.3% had subjective xerophthalmia after radioiodine treatment. They found that xerostomia persisted to the second year of follow-up in 20.3% of the cases and was still present >3 y after the last does of radioiodine in 15.2% of cases while xerophthalmia persisted to the second year of follow-up in 17.7% of cases and was still present in the third year of follow-up in 13.9% of cases. They also reported that salivary gland dysfunction was relatively frequent after RAI therapy and this was transient in most cases but persisted for a long period in some patients.

In ablation therapy with 131I, Rosário et al. [11] found that hypera-mylosemia and symptoms of acute si-aloadenitis occurred in 36.6% of the patients receiving recombinant-TSH (rhTSH) and 80% of the patients pre-pared by levothyroxine withdrawl. So, they reported a lower radiotoxicity with rhTSH.

Differentiated thyroid cancers are a relatively uncommon type of can-cer but are the most common cancers of the endocrine system, and their inci-dence has been rapidly increasing [12]. Differentiated thyroid cancers are treat-ed with high doses of 131I after total thyroidec-tomy. For this reason, history of RAI treatment should be given im-portance in patients applying either to emergency services or to ENT polyclin-ics with dry mouth.

In our patient, serum amylase level was measured as 1595 during the acute phase. Xero-stomia is an important problem increasing mor-bidity of the patients. For this reason, it is im-portant to prevent xerostamia by following serum amylase levels in symptomatic patients. Similar to bacterial parotitis and viral paroti-tis, serum amylase level increase is observed in parotitis occuring due to ablation therapy with 131I. Before claiming that salivary gland enlargement developing after radioio-dine is a complication of radiation, one has to rule out other parotitis possibili-ties by clinical and laboratory findings.
REFERENCES